MedTrace Logo

An Efficacy and Safety Study of LTG-001 Following Abdominoplasty

NCT07102459 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 343

Last updated 2026-04-29

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if LTG-001 works to treat post-operative / acute pain after an abdominoplasty procedure. It will also learn more information on the safety of LTG-001.

The main questions it aims to answer are:

Does drug LTG-001 treat the acute pain after surgical abdominoplasty over 48 hours? How tolerable is LTG-001 over 48 hours? What dose of LTG-001 is better for treating post-operative / acute pain?

Participants will:

Take LTG-001 bid after the surgical abdominoplasty. Remain at the clinic for approximately 48 hours during study dosing and return after two weeks for a safety check up. Report the pain relief during the 48 hours to record changes in the post-operative pain.

Conditions

  • Acute Pain
  • Postoperative Pain Control

Interventions

DRUG

Experimental: LTG-001 High Dose

High Dose Active

DRUG

Experimental: LTG-001 Low Dose

Lower Dose Active

DRUG

Active Comparator: HB/APAP

Active Comparator

DRUG

Placebo Comparator

Placebo

Sponsors & Collaborators

  • Latigo Biotherapeutics

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-24
Primary Completion
2026-01-07
Completion
2026-01-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07102459 on ClinicalTrials.gov